Download MendeleySynthesis and Evaluation of Novel Alpha-Amino Cyclic Boronates as Inhibitors of Hcv Ns3 Protease.
Li, X., Zhang, Y.-K., Liu, Y., Ding, C.Z., Li, Q., Zhou, Y., Plattner, J.J., Baker, S.J., Qian, X., Fan, D., Liao, L., Ni, Z.-J., White, G.V., Mordaunt, J.E., Lazarides, L.X., Slater, M.J., Jarvest, R.L., Edge, C.M., Hubbard, J.A., Nassau, P., Mcdowell, B., Skarzynski, T.J., Thommes, P., Ellis, M., Rowland, P., Somers, D.O., Kazmierski, W.M., Grimes, R.M., Wright, L.L., Smith, G.K., Zou, W., Wright, J., Pennicott, L.E.(2010) Bioorg Med Chem Lett 20: 3550
- PubMed: 20493689
- DOI: https://doi.org/10.1016/j.bmcl.2010.04.129
- Primary Citation of Related Structures:
2XCF, 2XCN - PubMed Abstract:
We have designed and synthesized a novel series of alpha-amino cyclic boronates and incorporated them successfully in several acyclic templates at the P1 position. These compounds are inhibitors of the HCV NS3 serine protease, and structural studies show that they inhibit the NS3 protease by trapping the Ser-139 hydroxyl group in the active site. Synthetic methodologies and SARs of this series of compounds are described.
Organizational Affiliation:
Anacor Pharmaceuticals, Inc., Palo Alto, CA 94303, USA. xli@anacor.com
